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The 12th World Conference on Lung Cancer, organized by the International Association for the 
Study of Lung Cancer (IASLC), was held in Seoul, Korea on 2–6 September 2007, attaining similar 
success to the previous conference held in Barcelona in 2005. The proceedings were published as 
a supplement to the Journal of Thoracic Oncology, the official journal of the IASLC. The IASLC is a 
multidisciplinary society, including all aspects related to lung cancer, such as epidemiology, 
prevention, early diagnosis, imaging, staging, multimodality management, targeted therapies and 
numerous others. Since its early meetings, the IASLC has been a pioneer in including novel 
information on molecular biology. Prominent groups from the USA, Asia and Europe presented 
novel information in all areas. More than 2000 abstracts were presented, and more than 4500 
investigators participated in the meeting. The participation of numerous Spanish investigators was 
reflected in the presentations. Due to space constraints, we will highlight only some of the Spanish 
presentations, with the understanding that many other important papers were also presented (see 
Journal of Thoracic Oncology August 2007; Vol. 2; www.jto.org). In addition, some large phase 
III studies promoted by pharmaceutical firms are not discussed here, particularly as the results were 
not sufficiently relevant for clinical practice and associated translational research 
was not performed, which makes it difficult to understand which subgroup of patients can benefit 
from some new therapies. 
One important novelty at the conference was the presentation of the IASLC Lung Cancer Staging 
Project. The IASLC established this project in 1998 in order to make recommendations for the 
seventh edition of the TNM Classification of Malignant Tumors (to be published in 2009). 
Adequate data were available on 67,725 cases of non small cell lung cancer (NSCLC) treated with 
all modalities of care between 1990 and 2000. The suggestions include additional cutoffs for tumour 
size, with tumours >7 cm moving from T2 to T3. They also suggest that T2b N0 M0 cases be moved 
from stage IB to stage IIA, that T2a N1 M0 cases be moved from stage IIB to IIA, and that T4 N0- 
1 M0 cases be moved from stage IIIB to IIIA. The proposed changes would improve the alignment 
of TNM stage with prognosis and, in certain subsets, with treatment. Complete information on this 
project has been published in different articles. 
Several of the sessions at the conference were related to new molecules involved in tumour 
development, diagnosis and treatment. John Minna presented different approaches for translating 
new discoveries in lung cancer pathogenesis to clinical applications. These include: 
genome-wide approaches, biomarkers for early diagnosis, inherited susceptibility to lung cancer, 
targeted therapy, development of preclinical lung cancer systems for drug exposure 
and expression profile signature development, genome-wide approaches to discovery of new 
therapeutic targets including synthetic lethal screens, and new discoveries on lung cancer stem 
cells. Ilona Linnoila gave an update on new mouse models used in lung cancer research. 
These models are more complex due to the complex genetics of lung cancer and may include 
models comprising mutations in the K-ras oncogene and different alleles of p53 which associate 
with stromal metaplasias and distant metastasis characteristics of human lung adenocarcinomas. 
Advances in imaging technologies applied to genetically engineered mice led to the development of 
new in vivo imaging techniques such as bioluminescence imaging in tumorigenesis. Finally in this 
session, Jerry Shay presented the characterisation of organotypic lung cultures expressing hTERT. 
Human bronchial epithelial cells are immortalised by expression of hTERT and cdkk4. These cells 
are able to differentiate into both mucous and ciliated epithelial cells when placed in 3D cultures. 
When these cells are transfected with KrasV12 and p53 is inactivated, they show an invasive 
phenotype, and when inoculated into the lungs of immunosuppressed mice, they develop into 
adenocarcinoma and squamous cell carcinoma. This indicated that human bronchial epithelial cells 
expressing cdk4 and hTERT fulfil the definition of cancer stem cells as they have self-renewal 
capacity. Results were also presented on the application of anti-telomerase strategies for cancer 
treatment. As activation of telomerases is a requisite for the growth of cancer stem cells, human 
lung spheroids were treated with the telomerase inhibitor GRN163L, and results showed a decrease 
in expression of stem cell markers. Therefore, it is tempting to speculate that treatment of lung 
tumours with GRN163L may lead to depletion of the stem cell population. 
An appealing session on genetics and epigenetics in lung carcinogenesis was also presented. 
Steven Belinsky based his talk on the use of promoter methylation detection in different genes to be 
used in screening for early detection of lung cancer in smokers. A panel of 14 genes was used 
whose promoter methylation was detected in sputum. Six of 14 genes were associated with >50% 
increase in lung cancer risk. The concomitant methylation of three or more of these six genes was 
associated with a 6.5-fold increased cancer risk and a sensitivity and specificity of 64%. An 
interesting report was also presented on the identification of genetic determinants for gene 
methylation based on the hypothesis that diminished DNA repair is associated with an increased 
methylation index. 
Adi F. Gazdar used a novel method to study preneoplasias based on the introduction of tumour-
associated genes into bronchial immortalised preneoplastic cultures. Introduction of Kras or p53 
knockdown or both into these cells induced the development of biological features suggestive 
of preneoplastic respiratory epithelium, indicating that they are useful models for studying lung 
preneoplasia. In the prognostic factor session, Rafael Rosell presented a study on the levels of 5 
transcripts of the caretaker genes ERCC1, MZF1, BRCA1, TWIST and TRX1. The samples included 
126 resected NSCLCs with the aim to identify patients with a high risk of relapse. Increased BRCA1 
was associated with shorter survival, indicating that BRCA1 assessment could be useful for 
customising adjuvant chemotherapy. (Complete information on this study has been published). 
Rosario Perona presented the preliminary results of a pharmacogenomic study performed with the 
aim of identifying gene profiles associated with pemetrexed response in surgical samples of 
NSCLC. The results indicated that 168 genes were able to predict in vitro response to pemetrexed 
treatment with a specificity of 76% and 84% respectively for sensitive and resistant samples. 
In early-stage NSCLC, Enriqueta Felip presented the Spanish Lung Cancer Group (SLCG) phase III 
NATCH trial, designed to address whether neoadjuvant or adjuvant paclitaxel/carboplatin improves 
disease-free survival compared to surgery alone in early-stage NSCLC. Six hundred and sixteen 
patients with clinical stage I (>2 cm), II, T3N1 NSCLC were randomised to surgery alone or three 
cycles of neoadjuvant paclitaxel 200 mg/m2 plus carboplatin AUC 6 on day 1 every 3 weeks, or 
surgery followed by 3 cycles of adjuvant paclitaxel plus carboplatin on the same schedule. 
Major radiographic response has been observed in 59% of patients. Median tumour size was 4.5 
cm at baseline CT scan and 2.5 cm at surgery in the neoadjuvant arm. At surgery, 9% of patients 
had pathologic complete response; 75% N0-1 disease (with persistent T tumour), and 15% had 
pathologic N2 disease. Neoadjuvant chemotherapy in early NSCLC has proven feasible and safe in 
this large multicentre sample. Mature survival results of the NATCH trial are expected in 2009. 
In locally advanced NSCLC, Pilar Garrido presented the SLCG phase II trial of concomitant 
chemoradiation plus induction of consolidation chemotherapy in unresectable stage IIIB NSCLC. 
One hundred and fifty-one patients were initially randomised to sequential treatment (arm A), 
concurrent chemoradiation followed by consolidation chemotherapy (arm B) or induction 
chemotherapy followed by concurrent chemoradiation (arm C). All patients received two cycles of 
docetaxel 40 mg/m2 on days 1 and 8 plus gemcitabine 1200 mg/m2 on days 1 and 8 as induction 
or consolidation therapy. Concomitant treatment was docetaxel 20 mg/m2 and carboplatin AUC 2 
weekly plus 60 Gy radiation. Toxicity grade 3–4 by CTC and RTOG criteria was: oesophagitis 
19.5% (arm B) and 14.2% (arm C); pneumonitis 8.8% (arm B) and 10% (arm C). Response 
rates were 57% (arm B) and 56.9% (arm C). A trend towards longer time to progression was 
observed in arm C but overall survival was similar in both arms (B: 14.3 months, C: 14.7 months; 
p=0.38). 
Manuel Domine presented a SLCG study in stage IV NSCLC patients treated with chemotherapy, 
showing the potential relevance of specific single nucleotide polymorphisms (SNPs). ERCC6 
(alternate name CSB) is involved in both transcription coupled and base excision DNA repair, and 
the ERCC6 C-6530>G SNP is involved in gene regulation. Different levels of ERCC6 mRNA 
expression have been observed in cells according to the ERCC6-6530 genotype. The ERCC6 C-
6530>G SNP was examined in 309 stage IV NSCLC patients treated with docetaxel/cisplatin or 
gemcitabine/cisplatin. No differences in genotype were observed according to age, gender, 
performance status (PS), histology, chemotherapy regimen or second-line treatment. Overall time to 
progression was 5.4 months and median survival was 9.9 months, with no differences according to 
ERCC6 SNP types. However, when patients were broken down by chemotherapy regimen, time 
to progression (p=0.04) and median survival (p=0.46) were longer for CC patients treated with 
gemcitabine/cisplatin than for CC patients treated with docetaxel/cisplatin. ERCC6 C-6530>G SNP 
may confer differential sensitivity to gemcitabine or docetaxel in combination with cisplatin. 
The IASLC World Conference on Lung Cancer (http://www.iaslc.org) is celebrated bi-annually, and 
the next conference will be held in 2009 in San Francisco, and the following in 2011 in Amsterdam. 
The venue for the conference alternates between Asia, North America and Europe. However, due to 
the rapid pace of innovation in lung cancer research, a joint lung cancer meeting will now be held 
annually, sponsored jointly by IASLC and the European Society of Medical Oncology (ESMO). The 





Table 1 ERCC6 genotypes and chemotherapy outcome in stage IV NSCLC  
ERCC6  N  TTP (m)  95% CI  p  
CC     0.04  
Doc/Cis  75  5.4  3.1–7.7   
Gem/Cis  31  7  2.5–11.4   
GG     0.90  
Doc/Cis  22  5.9  4.3–7.5   
Gem/Cis  17  4  0.4–7.6   
CG     0.95  
Doc/Cis  99  5.2  4–6.4   
Gem/Cis  56  6  4.8–7.2   
 
